Ohyama Ayumu, Higashi Taishi, Motoyama Keiichi, Arima Hidetoshi
Department of Physical Pharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto 862-0973, Japan; Program for Leading Graduate Schools 'Health Life Science: Interdisciplinary and Glocal Oriented (HIGO) Program', Kumamoto University, Japan.
Department of Physical Pharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto 862-0973, Japan.
Int J Biol Macromol. 2017 Jun;99:21-28. doi: 10.1016/j.ijbiomac.2017.02.045. Epub 2017 Feb 14.
We previously developed a tumor-selective siRNA carrier by preparing polyamidoamine dendrimer (generation 4, G4) conjugates with α-cyclodextrin and folate-polyethylene glycol (Fol-PαC (G4)). In the present study, we developed ternary complexes of Fol-PαC (G4)/siRNA with low-molecular-weight-sacrans to achieve more effective siRNA transfer activity. Among the different molecular-weight sacrans, i.e. sacran 100, 1000 and 10,000 (MW 44,889Da, 943,692Da and 1,488,281Da, respectively), sacran 100 significantly increased the cellular uptake and the RNAi effects of Fol-PαC (G4)/siRNA binary complex with negligible cytotoxicity in KB cells (folate receptor-α positive cells). In addition, the ζ-potential and particle size of Fol-PαC (G4)/siRNA complex were decreased by the ternary complexation with sacran 100. Importantly, the in vivo RNAi effect of the ternary complex after the intravenous administration to tumor-bearing BALB/c mice was significantly higher than that of the binary complex. In conclusion, Fol-PαC (G4)/siRNA/sacran 100 ternary complex has a potential as a novel tumor-selective siRNA delivery system.
我们之前通过制备与α-环糊精和叶酸-聚乙二醇(Fol-PαC (G4))偶联的聚酰胺胺树枝状大分子(第4代,G4)开发了一种肿瘤选择性siRNA载体。在本研究中,我们开发了Fol-PαC (G4)/siRNA与低分子量葡聚糖的三元复合物,以实现更有效的siRNA转染活性。在不同分子量的葡聚糖中,即葡聚糖100、1000和10,000(分子量分别为44,889Da、943,692Da和1,488,281Da),葡聚糖100显著增加了Fol-PαC (G4)/siRNA二元复合物在KB细胞(叶酸受体-α阳性细胞)中的细胞摄取和RNAi效应,且细胞毒性可忽略不计。此外,与葡聚糖100形成三元复合物后,Fol-PαC (G4)/siRNA复合物的ζ电位和粒径降低。重要的是,将三元复合物静脉注射给荷瘤BALB/c小鼠后的体内RNAi效应显著高于二元复合物。总之,Fol-PαC (G4)/siRNA/葡聚糖100三元复合物具有作为新型肿瘤选择性siRNA递送系统的潜力。